Odanacatib: An emerging novel treatment alternative for postmenopausal osteoporosis

Women's Health

Volumn 11, Issue 6, 2015, Pages 805-814

  Schultz, Thomas C ^a   Valenzano, Jonathan P ^a   Verzella, Jessica L ^a   Umland, Elena M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

bone mineral density; cathepsin K; drug review; odanacatib; postmenopausal osteoporosis

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; COLECALCIFEROL; ODANACATIB; PLACEBO; BIPHENYL DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADJUVANT THERAPY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; CYSTITIS; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; FRACTURE; HEADACHE; HUMAN; LIMB PAIN; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORPHEA; MUSCULOSKELETAL PAIN; NAUSEA; NOSE OBSTRUCTION; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; RHINOPHARYNGITIS; RHINORRHEA; SINGLE DRUG DOSE; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; BONE; BONE REMODELING; DRUG EFFECTS; FEMALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

BIPHENYL COMPOUNDS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CATHEPSIN K; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 84951981684     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.15.39     Document Type: Article

References (46)

1. Zallone A. Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann. NY Acad. Sci. 1068, 173-179 (2006).
2. Office of the Surgeon General (US). Bone health and osteoporosis: A report of the Surgeon General. Office of the Surgeon General (US) , MD, USA. www.ncbi.nlm.nih.gov/books
3. Rosen CJ. The cellular and clinical parameters of anabolic therapy for osteoporosis. Crit. Rev. Eukaryot. Gene. Expr. 13, 25-38 (2003).
4. Cosman F, De beur SJ, Leboff MS et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos. Int. 25(10), 2359-2381 (2014).
5. Wright NC, Looker AC, Saag KG et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J. Bone Miner. Res. 29(11), 2520-2526 (2014).
6. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17(1), 25-54 (2010).
7. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King AB, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J. Bone Miner. Res. 22(3), 465-475 (2007).
8. National Committee for Quality Assurance. HEDIS & Performance Measurement. Proposed Changes to Existing Measure for HEDIS®1 2015: Osteoporosis Management in Women Who Had a Fracture (OMW). Washington, DC, USA. www.ncqa.org
9. Lyritis GP, Georgoulas T, Zafeiris CP. Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis. Ann. NY Acad. Sci. 1205, 277-283 (2010).
10. Cosman F. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches. Curr. Osteoporos. Rep. 12(4), 385-395 (2014).
11. Mcclung M. Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required? Clin. Obstet. Gynecol. 56(4), 743-748 (2013).
12. Das S, Crockett JC. Osteoporosis-A current view of pharmacological prevention and treatment. Drug Des. Devel. Ther. 7, 435-448 (2013).
13. Black DM, Thompson DE, Bauer DC et al. Fracture risk reduction with alendronate in women with osteoporosis: The fracture intervention trial. FIT research group. J. Clin. Endocrinol. Metab. 85(11), 4118-4124 (2000).
14. Eriksen EF, Díez-pérez A, Boonen S. Update on longterm treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review. Bone 58, 126-135 (2014).
15. Shane E, Burr D, Ebeling PR et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 25(11), 2267-2294 (2010).
16. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/ osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg. 63(11), 1567-1575 (2005).
17. Thompson RN, Phillips JR, McCauley SH, Elliott JR, Moran CG. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J. Bone Joint Surg. Br. 94(3), 385-390 (2012).
18. Fleisher KE, Jolly A, Venkata UD, Norman RG, Saxena D, Glickman RS. Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy. J. Oral Maxillofac. Surg. 71(3), 513-519 (2013).
19. Assael LA. Oral bisphosphonates as a cause of bisphosphonaterelated osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J. Oral Maxillofac. Surg. 67(Suppl. 5), 35-43 (2009).
20. Lagari VS, Mcaninch E, Baim S. Considerations regarding adherence of anti-osteoporosis therapy. Postgrad. Med. 127(1), 92-98 (2015).
21. Rizzoli R. Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis. Ther. Adv. Musculoskelet. Dis. 2(1), 3-16 (2010).
22. Wensel TM, Iranikhah MM, Wilborn TW. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. Pharmacotherapy 31(5), 510-523 (2011).
23. Tsai JN, Uihlein AV, Lee H et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: The DATA Study randomized trial. Lancet 382, 50-56 (2013).
24. Reid IR. Efficacy, effectiveness and side effects of medications used to prevent fractures. J. Intern. Med. 277(6), 690-706 (2014).
25. Curtis JR, Delzell E, Chen L et al. The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J. Bone Miner. Res. 26, 683-688 (2011).
26. Brömme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin. Investig. Drugs 18, 585-600 (2009).
27. Kumar S, Dare L, Vasko-Moser JA et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 40, 122-131 (2007).
28. Ng KW. Potential role of odanacatib in the treatment of osteoporosis. Clin. Interv. Aging 7, 235-247 (2012).
29. Gauthier JY, Chauret N, Cromlish W et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg. Med. Chem. Lett. 18(3), 923-928 (2008).
30. Pérez-castrillón JL, Pinacho F, De luis D, Lopezmenendez M, Dueñas laita A. Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women. J. Osteoporos. doi: 10.4061/2010/401581 (2010) (Epub ahead of print).
31. Duong LT. Therapeutic inhibition of Cathepsin K-reducing bone resorption while maintaining bone formation. Bonekey Rep. 1, 67 (2012).
32. Kassanhun K, McIntosh I, Koeplinger K et al. Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans. Drug Metab. Dispos. 42(5), 818-827 (2014).
33. Stoch SA, Zajic S, Stone JA et al. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics-results from single oral dose studies in healthy volunteers. Br. J. Clin. Pharmacol. 75(5), 1240-1254 (2013).
34. Stoch SA, Zajic S, Stone J. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled Phase I studies. Clin. Pharmacol. Ther. 86(2), 175-182 (2009).
35. Anderson MS, Gendrano IN, Liu C et al. Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women. J. Clin. Endocrinol. Metab. 99(2), 552-560 (2014).
36. Bone HG, Mcclung MR, Roux C et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density. J. Bone Miner. Res. 25(5), 937-947 (2010).
37. Eisman JA, Bone HG, Hosking DJ et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J. Bone Miner. Res. 26(2), 242-251 (2011).
38. Langdahl B, Binkley N, Bone H et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a Phase 2 study. J. Bone Miner. Res. 27(11), 2251-2258 (2012).
39. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14), 1344-1352 (1999).
40. Miller PD, Recker RR, Reginster JY et al. Efficacy of monthly oral ibandronate is sustained over 5 years: The MOBILE long-term extension study. Osteoporos. Int. 23(6), 1747-1756 (2012).
41. Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX), a randomized trial. JAMA 296(24), 2927-2938 (2006).
42. Bonnick S, De villiers T, Odio A et al. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: A randomized placebo-controlled trial. J. Clin. Endocrinol. Metab. 98(12), 4727-4735 (2013).
43. Brixen K, Chapurlat R, Cheung AM et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: A randomized trial. J. Clin. Endocrinol. Metab. 98(2), 571-580 (2013).
44. Bone HG, Dempster DW, Eisman JA et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int. 26(2), 699-712 (2015).
45. Recker R, Dempster D, de Villiers T et al. Effects of odanacatib on bone structure and quality in postmenopausal women with osteoporosis: results from the Phase III longterm odanacatib fracture trial (LOFT). J. Bone Miner. Res. 29(Suppl. 1).
46. Nakamura T, Shiraki M, Fukunaga M et al. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis-A double-blind, randomized, dose-finding study. Osteoporos. Int. 25(1), 367-376 (2014).